Fresenius SE

Overview Key strengths Key risks Leading market positions within the Spanish and German private hospital segments through Helios, and intravenous (IV) generics and clinical nutrition products through Kabi. Regulatory changes in the German hospital market could pressure profitability in the future. Presence across the entire patient care continuum--through hospitals, medications, and medical devices--with good geographic diversity and organic growth prospects. Exposure to pricing pressure, particularly for IV generics across the company's main markets. Track record of positive free operating cash flow (FOCF) supporting debt reduction prospects, with a well-established financial policy target of net debt leverage that supports an investment-grade rating.Sizable and highly liquid stake in the world's largest dialysis business, Fresenius Medical Care (FMC), which affords significant financial flexibility

...FreseniusSE's third-quarter results show a resilient performance, with the divestment of Vamed reducing its business complexity and improving its profitability. Reported year-to- date EBITDA is about 2.65 billion (margin 16.6% versus 16.1% last year) with FOCF of about 988 million and debt reducing to 13.3 billion, from 15.8 billion at Dec. 31, 2023, as we...

Full Report